Substance
ID:1227
Names and Identifiers
IUPAC name
N-[4-oxo-2-(2H-1,2,3,4-tetrazol-5-yl)-4H-chromen-7-yl]-4-(4-phenylbutoxy)benzamide
IUPAC Traditional name
@pranlukast
Synonyms
ONO-RS 411Pranlukast
Properties
No Data Available
Click here to submit data
Molecule Details
Drug Groups
approved
Description
Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
Indication
Used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.
Pharmacology
Pranlukast is a cysteinyl leukotriene receptor-1 antagonist.
Toxicity
Side effects include headache, abdominal or stomach pain, cough, dental pain, dizziness, fever, heartburn, skin rash, stuffy nose, weakness or unusual tiredness.
Affected Organisms
Humans and other mammals
Biotransformation
Hepatic
References
•
Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S: Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma. Drug Metab Pharmacokinet. 2006 Apr;21(2):133-9.
[Pubmed]
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
• Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S: Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma. Drug Metab Pharmacokinet. 2006 Apr;21(2):133-9. Pubmed